We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Here's Why You Should Invest in Masimo (MASI) Right Now
Read MoreHide Full Article
Masimo Corporation (MASI - Free Report) is currently one of the top performing stocks in the Med Tech space. The company’s strong product portfolio and global expansion are major tailwinds.
Shares Shine Bright
Over the past month, shares of the global medical technology company have rallied 5.2%, ahead of the S&P 500 index’s gain of 3% and the industry’s 0.2%.
Three estimates have moved north in the last 60 days, with no movement in the opposite direction. During the same period, the Zacks Consensus Estimate for earnings per share rose 12.9% to 70 cents.
Consequently, the company has a Zacks Rank #2 (Buy), which indicates expectations of outperformance in the near term.
Let’s find out whether the recent positive trends can keep driving this stock in the long run.
What Makes It an Attractive Pick?
Promising Earnings
Masimo reported solid fourth-quarter earnings of 72 cents per share, up 37.3% on year-over-year basis. Revenues improved 22.9% to $225.2 million, compared with the year-ago quarter. The upside was primarily driven by a 42.5% year-over-year hike in revenues from Masimo rainbow products.
Broad Product Spectrum
Masimo gains from a solid product portfolio. The flagship SET pulse oximeter solution is rapidly gaining traction over conventional pulse oximeters. The company’s newborn screening application, Eve, recently received CE Mark.
Furthermore, Masimo has been launching products that target the general floor of hospitals and consumer market. The company recently introduced MightySat fingertip pulse oximeter for personal use. Products like Patient SafetyNet Series 5000, O3 regional oximetry, iSpO2 Mobile health pulse oximeter for Android also deserve a mention.
Global Expansion
Recently, Masimo expanded its operations in India. The company announced that NU Hospitals, a leading nephrology care center in India, has adopted Masimo technologies across its continuum of care. This is to consolidate the company’s foothold in the global MedTech Space.
athenahealth has an expected long-term growth rate of 17.7% and projected earnings per share growth rate of 21.5%.
Bio-Rad has an expected long-term growth rate of 20% and projected earnings per share growth rate of 20%.
Centene has an expected long-term growth rate of 14.4% and projected earnings per share growth rate of 14.4%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this year, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others.
Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Here's Why You Should Invest in Masimo (MASI) Right Now